1-deoxynojirimycin has been researched along with cyclosporine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, M; Tao Ye, J; Wan, S; Wu, J; Xie, P; Zhang, XL; Zhou, X | 1 |
| Dong, H; Liu, M; Wang, S; Xiang, T; Yang, K; Zhang, XL; Zhou, YD | 1 |
2 other study(ies) available for 1-deoxynojirimycin and cyclosporine
| Article | Year |
|---|---|
Specific inhibition effects of N-pentafluorobenzyl-1-deoxynojirimycin on human CD4+ T cells.
Topics: 1-Deoxynojirimycin; Benzyl Compounds; CD4-Positive T-Lymphocytes; Cyclosporine; Cytokines; Humans; Immunosuppressive Agents; Interleukin-4; Leukocytes, Mononuclear; Th2 Cells | 2004 |
An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
Topics: 1-Deoxynojirimycin; Animals; Benzyl Compounds; CD4-Positive T-Lymphocytes; Chemistry, Pharmaceutical; Cyclosporine; Cytoplasm; Drug Design; Gene Expression Regulation; Humans; Immunosuppressive Agents; Interleukin-4; Leukocytes, Mononuclear; Mice; Models, Chemical; Schistosoma japonicum; Schistosomiasis; Signal Transduction; Spleen; Th2 Cells; Time Factors | 2012 |